Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials

Bettina Diekamp¹
 Stephane Borentain²
 Dong-Jing Fu³
 Robert Murray⁴
 Kristin Heerlein¹
 Qiaoyi Zhang⁵
 Cornelius Schüle⁶
 Maju Mathews²

¹Department of Medical and Scientific Affairs, Janssen-Cilag GmbH, Neuss, Germany; ²Department of Global Medical Affairs, Janssen Research & Development LLC, Titusville, NJ, USA; ³Department of Neuroscience Clinical Development, Janssen Research & Development LLC, Titusville, NJ, USA; ⁴Neuroscience Clinical Biostatistics, Janssen Research & Development LLC, Titusville, NJ, USA; ⁵Global Market Access, Neuroscience, Janssen Global Services, LLC, Titusville, NJ, USA; ⁶Ludwig-Maximilians-University Munich, Clinic for Psychiatry and Psychotherapy, Munich, Germany

Purpose: The impact of benzodiazepines on the efficacy and safety of esketamine as a rapid-acting antidepressant remains unclear.

Materials and Methods: Data from two identically designed, randomized double-blind studies were pooled and analyzed on a post-hoc basis. In both studies, adults with major depressive disorder with acute suicidal ideation or behavior were randomized to placebo or esketamine 84 mg nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care (initial hospitalization and newly initiated or optimized oral antidepressant[s]). Efficacy and safety were analyzed in two groups based on whether patients used concomitant benzodiazepines, which were prohibited within 8 hours before and 4 hours after the first dose of esketamine and within 8 hours of the primary efficacy assessment at 24 hours. The primary efficacy endpoint – change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score – was analyzed using ANCOVA.

Results: Most patients (309/451, 68.5%) used concomitant benzodiazepines. Greater decrease in MADRS total score was observed with esketamine (mean [SD]: –16.1 [11.73]) versus placebo (–12.6 [10.56]) at 24 hours (least-squares mean difference: –3.7, 95% CI: –5.76, –1.59). The differences between the esketamine and placebo groups were clinically meaningful, irrespective of benzodiazepine use (benzodiazepine: –4.3 [–6.63, –1.89]; no benzodiazepine: –3.1 [–6.62, 0.45]). Among patients taking esketamine, change in MADRS total score was not significantly different between patients taking benzodiazepines (–15.8 [11.27]) versus those not taking benzodiazepines (–16.8 [12.82]) (least-squares mean difference: 1.1, [–2.24, 4.45]). Among esketamine-treated patients, the incidence of sedation was higher with benzodiazepine use, whereas dissociation was similar.

Conclusion: Benzodiazepines do not meaningfully affect the rapid-acting antidepressant effect of esketamine at 24 hours post-first dose among patients with MDD and acute suicidal ideation or behavior.

Keywords: esketamine, benzodiazepine, depression, suicidal ideation, rapid-acting

Correspondence: Bettina Diekamp
 Department of Medical and Scientific Affairs, Janssen-Cilag GmbH, Johnson & Johnson Platz 1, Neuss, 41470, Germany
 Tel +49-21379556179
 Email bdiekamp@its.jnj.com

Introduction

More than 1 in every 5 adults experience major depressive disorder (MDD) episodes over their lifetime.^{1,2} Almost a third of patients with MDD attempt suicide (lifetime prevalence 31% [95% confidence interval {CI} 27–34%]),³ most

experiencing suicidal ideation beforehand.⁴ Despite the need for prompt intervention, oral antidepressants can take a month or more for optimal effect.^{5,6} Until recently, there was no approved pharmacotherapy for the rapid reduction of depressive symptoms in patients with MDD and acute suicidal ideation or behavior.^{6,7}

Benzodiazepines are often prescribed by clinicians, in addition to antidepressant, for relieving acute agitation, anxiety, or insomnia in patients with depression,⁸ notably during an acute suicidal crisis⁹ and are advocated by treatment guidelines in some countries, primarily for acute treatment of these patients.^{6,10} However, the role of benzodiazepines in the setting of psychiatric emergency is a matter of debate,¹¹ and concerns around abuse, addiction, and tolerance/rebound are well known.¹²

Esketamine (the S-enantiomer of ketamine racemate), a first-in-class glutamatergic N-methyl-D-aspartate receptor antagonist, was approved in 2019 for treatment-resistant depression (TRD). More recently, esketamine was approved in the United States for the treatment of depressive symptoms in adults with MDD with acute suicidal ideation or behavior,¹³ and in the European Union, co-administered with oral antidepressant therapy, in adults with a moderate-to-severe episode of MDD, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.¹⁴ These most recent approvals for esketamine nasal spray were primarily based on efficacy and safety findings from two identically designed, Phase 3 global studies (ASPIRE I and ASPIRE II).^{15,16} In these studies, the esketamine plus standard-of-care group demonstrated rapid improvement of depressive symptoms over the placebo plus standard-of-care group as early as 4 hours and 24 hours after the first dose.

Benzodiazepines have been reported to attenuate ketamine's antidepressant response in a case report¹⁷ and small, single-center clinical studies of patients with TRD.^{18,19} Although consensus on the mechanism for the interaction is lacking, Albott et al¹⁹ suggested that benzodiazepine agonism of the γ -aminobutyric acid (GABA) A receptor decreases ketamine's excitatory glutamatergic signal transduction, thereby attenuating its therapeutic effect. We conducted a post hoc analysis of pooled data from the ASPIRE I and ASPIRE II studies in patients with MDD and acute suicidal ideation or behavior^{15,16} to examine the potential effects of benzodiazepines on the safety and rapid efficacy of esketamine nasal spray following first-dose treatment in these patients who were experiencing a psychiatric emergency and

in urgent need of symptom control. Specifically, the aims of the analyses were to: compare the efficacy of esketamine to that of placebo in patients with or without concomitant benzodiazepines; evaluate the impact of benzodiazepines on the rapid antidepressant effect of esketamine; and, determine the effects of benzodiazepines on the safety profile of esketamine.

Materials and Methods

Institutional review boards/ethics committees (names provided in [Table S1](#)) approved the ASPIRE I and ASPIRE II protocols and their amendments, written consent was obtained from all patients before they participated in the studies, both studies were conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and both studies are registered at clinicaltrials.gov (identifiers: NCT03039192 [registered 31 January 2017] and NCT03097133 [registered 27 March 2017]). The study methods pertaining to the work reported here are summarized below.

ASPIRE I and ASPIRE II were identically designed, double-blind, randomized, placebo-controlled phase 3 studies conducted between June 2017 and April 2019 in North America, Europe (both studies), Asia (ASPIRE I only), and South America (ASPIRE II only). The ASPIRE studies enrolled adults (18–64 years) with a diagnosis of MDD without psychotic features, according to Diagnostic and Statistical Manual of Mental Disorders 5th edition²⁰ (DSM-5) and confirmed by the Mini-International Neuropsychiatric Interview (MINI).²¹ Potential study participants were screened soon after arriving at an emergency department or being admitted to an inpatient psychiatric ward, where they were to stay for 5 days (14 days in several European Union countries) after entering the studies. To be eligible, patients must have had a current suicidal ideation with intent, confirmed by affirmative responses to MINI questions B3 (Think about suicide [killing yourself]?) and B10 (Intend to act on thoughts of killing yourself in the past 24 hours?) within 24 hours of randomization, been in clinical need of acute psychiatric hospitalization due to imminent suicide risk, and had a Montgomery-Asberg Depression Rating Scale²² (MADRS) total score >28 prior to the first dose of the study drug on day 1. Patients must have voluntarily agreed to comprehensive standard-of-care treatment, including the initial hospitalization. Key exclusion criteria were current or prior DSM-5 diagnosis of a psychotic disorder or MDD with psychotic features, current DSM-5 diagnosis of bipolar disorder, obsessive-compulsive disorder, antisocial personality disorder, or borderline personality

disorder, and DSM-5 diagnosis of moderate-to-severe substance or alcohol use disorder in the recent 6–12 months prior to screening. Full lists of the inclusion and exclusion criteria for each study are published.^{15,16}

Patients meeting eligibility criteria were randomized to 84 mg esketamine nasal spray or matching placebo nasal spray. Patients self-administered the study drug twice-weekly for 4 weeks, beginning on day 1, with dosing supervised by medical staff at the study centers. In addition, patients received standard-of-care oral antidepressant(s) – either monotherapy or antidepressant plus augmenting agents (ie, second antidepressant, an atypical antipsychotic, or a mood stabilizer) – determined by the investigator and initiated or optimized at the time they were randomized.

Benzodiazepines (dosage equivalent to lorazepam ≤ 6 mg/day) were allowed during the study, as long as they were not taken during the 8 hours preceding each intranasal study drug administration, the 4 hours following the first intranasal study drug administration, and within 8 hours of day 2 assessments (Figure 1). Prohibition of benzodiazepines during these hours before and after dosing and before day 2 assessments was driven by potential confounding due to benzodiazepine-related sedation on efficacy and safety assessments of esketamine.

Investigators assessed depressive symptom severity using MADRS, before and 4 and 24 hours after the first dose of intranasal esketamine or intranasal placebo (days 1–2), pre-dose at all successive visits during double-blind treatment, and 4 hours post-dose on day 25. A difference between treatment groups of 2 points or greater for change in total MADRS score was considered clinically meaningful.^{23,24}

Adverse events were monitored throughout the study. Dissociative symptoms were assessed pre-dose and 40 minutes and 1.5 hours post-dose on dosing days using the Clinician Administered Dissociative States Scale (CADSS).²⁵ Sedation/alertness was assessed every 15 minutes from predose to 1.5 hours postdose on dosing days using Modified Observer's Assessment of Alertness/Sedation scale (MOAA/S).²⁶

Statistical Analyses

Efficacy and safety were each analyzed by treatment arm and by benzodiazepine use (yes/no) in pooled data from the ASPIRE I and ASPIRE II studies. Point estimates of the treatment differences (either difference in means or proportions) and 95% CIs are reported. Of note, 95% CIs that do not include zero for differences in means and proportions correspond to a two-sided P-value that is less than 0.05 (ie, statistical significance). CIs were presented rather than P-values as they provide information on the direction and magnitude of the effect. As this was a post-hoc analysis, no adjustments for multiple comparisons were made.

For efficacy assessments, which were performed on day 2 (24 hours post-first dose), benzodiazepine users included patients who took a benzodiazepine(s) (standing or as-needed dosing) between day –2 and day 2. For safety assessments, including MOAA/S and CADSS that were assessed up to 1.5 hours post-dose, benzodiazepine users included patients who took a benzodiazepine(s) on day –2 and/or day –1 (before dosing of the study drug began).

Figure 1 Benzodiazepine dosing relative to study drug dosing.

Notes: Study Day 1 is the overall reference start date for the study, which is defined as the day a patient was randomized and received the first dose of study drug. The day prior to Day 1 is denoted as study Day –1, whereas the day after Day 1 is denoted as Day 2, and so on. Depressive symptom severity was assessed before and 4 and 24 hours after the first dose of intranasal study drug (Days 1–2) using MADRS. On Day 1, dissociative symptoms were assessed pre-dose and 40 minutes and 1.5 hours post-dose using the Clinician Administered Dissociative States Scale (CADSS), and sedation/alertness was assessed every 15 minutes from predose to 1.5 hours postdose on dosing days using Modified Observer's Assessment of Alertness/Sedation scale (MOAA/S).

Abbreviations: H, hour; MADRS, Montgomery-Asberg Depression Rating Scale.

Demographic and baseline characteristics were summarized by benzodiazepine use.

The primary efficacy endpoint – change in MADRS total score from baseline (day 1, predose) to 24 hours post-first dose (day 2) – was analyzed on last observation carried forward (LOCF) data using analysis of covariance (ANCOVA) with study number, treatment, analysis center within study number, standard-of-care antidepressant (as randomized), benzodiazepine group, and treatment-by-benzodiazepine group as factors, and baseline MADRS total score as a continuous covariate. A sensitivity analysis on the primary efficacy endpoint, based on the timing of benzodiazepine use (ie, between day –2 and day –1 and between day 1 and day 2) was conducted using ANCOVA.

In other analyses, frequency distributions were provided by the treatment and benzodiazepine (yes/no) group for responders to treatment (defined as $\geq 50\%$ decrease from the baseline MADRS total score) and patients in remission of depressive symptoms (defined as MADRS ≤ 12) at day 2, for adverse events with onset within 24 hours of treatment, and for CADSS total score and MOAA/S total score at day 1.

Results

In the ASPIRE studies, 456 patients were randomized to study drug, 229 to esketamine plus standard-of-care and 227 to placebo plus standard-of-care. Four patients (2 in each treatment group) were excluded from analyses of efficacy and safety because they did not receive a dose of intranasal study drug. One additional patient (in the esketamine group) was excluded from analyses of efficacy due to the absence of post-baseline MADRS assessments.

Benzodiazepine use was common during the period evaluated (ie, day –2 to day 2) (309/451, 68.5% of patients). Patients who did and those who did not receive benzodiazepines were generally similar with respect to demographic and baseline clinical characteristics, including depression severity (MADRS score) (Table 1).

Mean MADRS total score decreased from baseline to 24 hours post-first dose, with greater improvement in depressive symptoms among those treated with esketamine plus standard-of-care as compared to placebo plus standard-of-care in the overall population (mean [SD]: esketamine –16.1 [11.73] versus placebo –12.6 [10.56]) at 24 hours; least-squares [LS] mean difference: –3.7, 95% CI: –5.76, –1.59). Clinically meaningful improvement in depressive symptoms was observed with esketamine versus placebo in the subgroups of patients with or without

benzodiazepine use (Figure 2). The difference of LS means (95% CI) was –4.3 (–6.63, –1.89) for the patients taking benzodiazepines and –3.1 (–6.62, 0.45) for the patients who did not take benzodiazepines. Among esketamine-treated patients, no statistically significant difference was observed in the reduction of MADRS total score between patients taking benzodiazepines (mean [SD]: –15.8 [11.27]) versus those not taking benzodiazepines (–16.8 [12.82]) (difference of LS means [95% CI], 1.1 [–2.24, 4.45]). Sensitivity analyses on change in MADRS score from baseline to 24 hours post-first dose revealed similar results when timing of benzodiazepine use was defined by the period only before esketamine dose, and also by the period only after esketamine dose (Table S2).

On day 2, the proportion of patients who were responders and the proportion of patients in remission were numerically higher among those treated with esketamine plus standard-of-care as compared to placebo plus standard-of-care, with little influence by concomitant benzodiazepine use (Figure 3).

In terms of safety, dissociation was reported as a treatment-emergent (ie, within 24 hours of study drug administration) adverse event for 29.5% (67/227) of esketamine-treated patients and 3.6% (8/225) of placebo-treated patients, with incidence similar between those who did and did not take concomitant benzodiazepines within each treatment group (Table 2). In line with these findings, mean total CADSS score at 40 minutes following the first dose was increased from predose, substantially more so among the esketamine- versus the placebo-treated patients, but, within the esketamine group, similarly among those taking a benzodiazepine compared to those not taking a concomitant benzodiazepine. Mean total CADSS total score returned toward the predose level by 1.5 hours post-dose in all analysis groups.

More patients in the esketamine plus standard-of-care group (17/227 [7.5%]) had a MOAA/S score ≤ 3 (indicating moderate or greater sedation) on day 1, versus patients in the placebo plus standard-of-care group (2/225 [0.9%]). None of these patients required medical intervention. The incidence of sedation, based on adverse event reporting, was higher among esketamine-treated patients who had taken concomitant benzodiazepines compared to those who had not, and compared to placebo-treated patients, regardless of concomitant benzodiazepine usage (Table 2).

Most adverse events of dissociation were mild or moderate (esketa- mine 92.0%, placebo 100%) and had onset

Table 1 Demographic and Baseline Characteristics by Benzodiazepine Use in ASPIRE Studies (Safety Analysis Set)

Characteristic	All Patients		Benzodiazepine		No Benzodiazepine	
	Esketamine 84 mg + Standard-of-Care N=227 ^a	Placebo + Standard-of-Care N=225 ^a	Esketamine 84 mg + Standard-of-Care N=159	Placebo + Standard-of-Care N=150	Esketamine 84 mg + Standard-of-Care N=68	Placebo + Standard-of-Care N=75
Sex, n (%)						
Female	135 (59.5)	140 (62.2)	100 (62.9)	96 (64.0)	35 (51.5)	44 (58.7)
Male	92 (40.5)	85 (37.8)	59 (37.1)	54 (36.0)	33 (48.5)	31 (41.3)
Age, years						
Mean (SD)	40.5 (12.90)	39.6 (13.08)	41.7 (12.66)	40.0 (13.05)	37.7 (13.10)	38.9 (13.21)
Range	(18; 62)	(18; 64)	(18; 61)	(18; 64)	(19; 62)	(18; 64)
18–34, n (%)	81 (35.7)	87 (38.7)	48 (30.2)	56 (37.3)	33 (48.5)	31 (41.3)
35–54, n (%)	104 (45.8)	104 (46.2)	80 (50.3)	71 (47.3)	24 (35.3)	33 (44.0)
55–64, n (%)	42 (18.5)	34 (15.1)	31 (19.5)	23 (15.3)	11 (16.2)	11 (14.7)
Race, n (%)						
Asian	29 (12.8)	30 (13.3)	27 (17.0)	27 (18.0)	2 (2.9)	3 (4.0)
White	169 (74.4)	161 (71.6)	117 (73.6)	101 (67.3)	52 (76.5)	60 (80.0)
Other ^b	29 (12.8)	34 (15.1)	15 (9.4)	22 (14.7)	14 (20.6)	12 (16.0)
Region, n (%)						
Asia	26 (11.5)	27 (12.0)	25 (15.7)	25 (16.7)	1 (1.5)	2 (2.7)
Europe	117 (51.5)	106 (47.1)	84 (52.8)	68 (45.3)	33 (48.5)	38 (50.7)
North America	59 (26.0)	65 (28.9)	30 (18.9)	39 (26.0)	29 (42.6)	26 (34.7)
South America	25 (11.0)	27 (12.0)	20 (12.6)	18 (12.0)	5 (7.4)	9 (12.0)
Duration of current depressive episode, months						
N	200	212	145	142	55	70
Mean (SD)	42.3 (65.04)	41.8 (68.37)	40.9 (62.16)	39.3 (66.35)	46.0 (72.55)	47.0 (72.52)
Range	(1; 356)	(2; 445)	(1; 341)	(2; 445)	(2; 356)	(2; 339)
SOC antidepressant as randomized, n (%)						
Antidepressant monotherapy	105 (46.3)	108 (48.0)	68 (42.8)	70 (46.7)	37 (54.4)	38 (50.7)
Antidepressant plus augmentation therapy	122 (53.7)	117 (52.0)	91 (57.2)	80 (53.3)	31 (45.6)	37 (49.3)

(Continued)

Table 1 (Continued).

Characteristic	All Patients		Benzodiazepine		No Benzodiazepine	
	Esketamine 84 mg + Standard-of-Care N=227 ^a	Placebo + Standard-of-Care N=225 ^a	Esketamine 84 mg + Standard-of-Care N=159	Placebo + Standard-of-Care N=150	Esketamine 84 mg + Standard-of-Care N=68	Placebo + Standard-of-Care N=75
MADRS total score						
N	226	225	158	150	68	75
Mean (SD)	40.3 (5.60)	40.4 (6.04)	40.2 (5.58)	40.8 (5.82)	40.7 (5.56)	39.6 (6.43)
Range	(29; 56)	(29; 58)	(29; 56)	(29; 54)	(30; 56)	(29; 58)
CGI-SS-r, n (%)						
N	226	225	158	150	68	75
Normal, not at all suicidal	0	0	0	0	0	0
Questionably suicidal	6 (2.7)	6 (2.7)	3 (1.9)	4 (2.7)	3 (4.4)	2 (2.7)
Mildly suicidal	16 (7.1)	17 (7.6)	9 (5.7)	12 (8.0)	7 (10.3)	5 (6.7)
Moderately suicidal	64 (28.3)	61 (27.1)	48 (30.4)	35 (23.3)	16 (23.5)	26 (34.7)
Markedly suicidal	87 (38.5)	84 (37.3)	64 (40.5)	60 (40.0)	23 (33.8)	24 (32.0)
Severely suicidal	46 (20.4)	55 (24.4)	28 (17.7)	38 (25.3)	18 (26.5)	17 (22.7)
Among the most extremely suicidal patients	7 (3.1)	2 (0.9)	6 (3.8)	1 (0.7)	1 (1.5)	1 (1.3)
Prior suicide attempt, n (%)						
N	226	225	158	150	68	75
Yes	145 (64.2)	140 (62.2)	102 (64.6)	97 (64.7)	43 (63.2)	43 (57.3)
No	81 (35.8)	85 (37.8)	56 (35.4)	53 (35.3)	25 (36.8)	32 (42.7)
Suicide attempt within the last month, n (%)						
Yes	68 (30.0)	55 (24.4)	49 (30.8)	37 (24.7)	19 (27.9)	18 (24.0)
No	159 (70.0)	170 (75.6)	110 (69.2)	113 (75.3)	49 (72.1)	57 (76.0)

Notes: The benzodiazepine group contains patients who took benzodiazepines between day -2 and day 2.³Of 229 patients randomized to esketamine + standard-of-care and 227 patients randomized to placebo + standard-of-care, 2 patients in each treatment group were excluded from analyses of safety because they did not receive a dose of intranasal study drug.^bIncludes Black or African American, other races, multiple races, or not reported.

Abbreviations: CGI-SS-r, Clinical Global Impression-Severity revised version; MADRS, Montgomery-Asberg Depression Rating Scale; SD, standard deviation; SOC, Standard-of-Care.

Figure 2 MADRS total score: change from baseline to 24 hours post-first dose by benzodiazepine use in ASPIRE studies (LOCF).

Notes: MADRS total score ranges from 0 to 60; a higher score indicates a more severe condition. Negative change in score indicates improvement. Negative difference favors esketamine. The benzodiazepine group contains patients who took benzodiazepines between day -2 and day 2. The difference of LS means (95% CI) in reduction of MADRS total score between benzodiazepine and non-benzodiazepine users was 1.1 (-2.24, 4.45) for patients in the esketamine plus standard-of-care group and 2.3 (-0.96, 5.53) for patients in the placebo plus standard-of-care group.^aOf 229 patients randomized to esketamine + standard-of-care and 227 patients randomized to placebo + standard-of-care, 2 patients in each treatment group were excluded from analyses of efficacy because they did not receive a dose of intranasal study drug. In addition, 3 patients in the esketamine group did not have the necessary data to calculate change in MADRS at day 2. ^bBased on ANCOVA with study number, treatment, analysis center within study number, standard-of-care antidepressant as randomized, benzodiazepine group, and treatment-by-benzodiazepine group as factors, and baseline MADRS total score as a continuous covariate. ^cEsketamine + standard-of-care minus placebo + standard-of-care in each benzodiazepine group.

Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; LOCF, last observation carried forward; LS, least-squares; MADRS, Montgomery-Asberg Depression Rating Scale; SE, standard error.

within one hour of study drug administration (94.3% and 90.9% of events in the respective treatment groups). All events of sedation were mild or moderate and had onset within one hour of study drug administration.

Discussion

Patients with MDD having acute suicidal ideation or behavior are in a psychiatric emergency. During this psychiatric emergency, clinicians prescribe benzodiazepines for rapid

relief of acute agitation, anxiety, or insomnia, which accompanies depression in many patients.^{6,10,27,28} We observed high usage of benzodiazepines (69% of study patients) at the onset of the ASPIRE studies (day -2 to day 2), within the constraints of the protocol-specified time frame.

Among esketamine-treated patients, improvement in depressive symptoms was similar, regardless of benzodiazepine use. Concomitant treatment with benzodiazepines

Figure 3 MADRS response and remission rates 24 hours post-first dose by benzodiazepine use in ASPIRE studies. (A) Response. (B) Remission.

Notes: Response is defined as $\geq 50\%$ decrease from baseline MADRS total score. Remission is defined as MADRS total score ≤ 12 . The benzodiazepine group contains patients who took benzodiazepines between day -2 and day 2. ^aOf 229 patients randomized to esketamine + standard-of-care and 227 patients randomized to placebo + standard-of-care, 2 patients in each treatment group were excluded from analyses of efficacy because they did not receive a dose of intranasal study drug and 1 additional patient in the esketamine group was excluded due to absence of post-baseline MADRS assessments.

Abbreviation: MADRS, Montgomery-Asberg Depression Rating Scale.

Table 2 Treatment-Emergent Dissociation and Sedation by Benzodiazepine Use in ASPIRE Studies (Safety Analysis Set)

	All Patients		Benzodiazepine		No Benzodiazepine	
	Esketamine 84 mg + Standard-of-Care N=227 ^a	Placebo + Standard-of-Care N=225 ^a	Esketamine 84 mg + Standard-of-Care N=148	Placebo + Standard-of-Care N=140	Esketamine 84 mg + Standard-of-Care N=79	Placebo + Standard-of-Care N=85
Dissociation						
Adverse event of dissociation, n (%)	67 (29.5)	8 (3.6)	46 (31.1)	4 (2.9)	21 (26.6)	4 (4.7)
CADSS score on day 1, mean (SD)						
predose	1.4 (4.61)	1.4 (4.06)	1.7 (5.36)	1.4 (4.14)	1 (2.68)	1.4 (3.96)
40 minutes postdose	14.3 (12.58)	1.9 (4.23)	15.9 (13.20)	1.7 (4.15)	11.2 (10.75)	2.3 (4.35)
1.5 hours postdose	2.0 (3.69)	0.8 (2.99)	2.1 (3.92)	0.9 (3.36)	1.8 (3.18)	0.6 (2.29)
Sedation						
Adverse event of sedation, n (%)	13 (5.7)	3 (1.3)	12 (8.1)	2 (1.4)	1 (1.3)	1 (1.2)
MOAA/S ≤ 3 on day 1, n (%)	17 (7.5)	2 (0.9)	13 (8.8)	1 (0.7)	4 (2.7)	1 (0.7)

Notes: The benzodiazepine group contains patients who took benzodiazepines between day -2 and day -1. The most severe post-dose score for MOAA/S on day 1 were considered for each patient. Only dissociation and sedation adverse events with onset within 24 hours of start of first treatment were considered. ^aOf 229 patients randomized to esketamine + standard-of-care and 227 patients randomized to placebo + standard-of-care, 2 patients in each treatment group were excluded from analyses of safety because they did not receive a dose of intranasal study drug.

Abbreviations: CADSS, Clinician Administered Dissociative States Scale; MOAA/S, Modified Observer's Assessment of Alertness/Sedation.

(ie, taken between day -2 and day 2) did not augment or diminish the rapid, robust antidepressant effect observed after the first dose of esketamine in these patients (primary efficacy endpoint), which is specifically relevant in the setting of psychiatric emergencies.

The findings from the ASPIRE studies do not support prior studies in which benzodiazepines were shown to attenuate the acute antidepressant effect of ketamine (Ford et al¹⁷ [case study, n=1]; Frye et al¹⁸ [post-hoc analysis, n=10]; Albott et al¹⁹ [post-hoc analysis, n=14]; Andrashko et al²⁹ [n=47, excluded patients with suicidal risk assessed by clinical examination]). The disparity may be explained, at least in part, by the small sample size and uncontrolled methods of the ketamine studies and, perhaps, that the ketamine studies included patients who had TRD but were not in acute crisis. In a post-hoc analysis of 10 patients with TRD given ketamine infusions twice weekly for up to 2 weeks, Frye et al¹⁸ reported that non-responders received significantly higher mean daily doses of benzodiazepines than responders ($\geq 50\%$ decrease from baseline MADRS total score). Likewise, in a study of 47 patients with MDD and without suicidal risk who received a single ketamine infusion as an add-on to ongoing antidepressant treatment, Andrashko et al²⁹ reported a significantly lower response rate among those taking high-dose benzodiazepines (defined as >8 mg diazepam equivalent, n=13). And, in a post hoc analysis of 13 patients with TRD who received a ketamine infusion 3 times weekly for 2 weeks, Albott et al¹⁹ reported no significant differences between benzodiazepine and non-benzodiazepine users in response or remission rates, or depression relapse rate over 4-week follow-up, but those taking benzodiazepine took significantly longer time to reach these outcomes and experienced significantly shorter therapeutic effect.¹⁸

The incidences of esketamine-associated dissociation and sedation are consistent with expectations from TRD studies.^{13,14} Most events of dissociation and sedation were mild or moderate and began within one hour of study drug administration. Dissociation, based on adverse event reporting and post-dose mean total CADSS score, was more common with esketamine compared to placebo, and was not influenced by benzodiazepine use prior to esketamine dosing. Sedation, based on adverse event reporting and MOAA/S score ≤ 3 , was also more common with esketamine compared to placebo, especially so among those who had taken benzodiazepines prior to esketamine dosing. This result was expected given the well-known sedative effects of benzodiazepines.

The most important observation of the study is that the rapid antidepressant effect of esketamine nasal spray is not attenuated or augmented by the concomitant administration of benzodiazepines in patients with MDD and acute suicidal ideation or behavior. While clinicians often prescribe benzodiazepines in combination with conventional antidepressants for the initial treatment of anxiety, due to latency of efficacy of these antidepressants, this may not be necessary even in the initial phase of treatment with esketamine because of its rapid effect. In addition, the use of benzodiazepines during treatment with esketamine may lead to an increase in adverse events, particularly sedation, and may not reduce the incidence of dissociative effects at the beginning of esketamine treatment.

Limitations

Our results are limited by analyses being conducted on a post hoc basis. Furthermore, the ASPIRE studies did not allow concomitant benzodiazepine use within 8 hours of esketamine dosing and within 8 hours of primary efficacy (day 2) assessment; thus, we could not examine the potential effect of benzodiazepines on the efficacy or tolerability of esketamine if they were used together. And, the analyses reported herein are confined to effects following the first dose of esketamine, informing on the effects of benzodiazepine treatment in the context of the need for urgent control of symptoms; the impact of chronic benzodiazepine use on the long-term efficacy/safety of esketamine was not explored.

Conclusions

The findings from this analysis support the efficacy and safety of esketamine nasal spray for MDD patients with acute suicidal ideation or behavior, irrespective of benzodiazepine use. Specifically, benzodiazepines had minimal impact on the rapid antidepressant efficacy of esketamine, but increased the occurrence of sedation. Therefore, the use of benzodiazepines for patients being treated with esketamine for psychiatric crisis may not be warranted. Further investigation is needed to confirm and expand upon these findings.

Abbreviations

ANCOVA, analysis of covariance; CADSS, Clinician Administered Dissociative States Scale; CGI-SS-r, Clinical Global Impression–Severity revised version; CI, confidence interval; DSM-5, Diagnostic and Statistical Manual of Mental Disorders 5th edition; LOCF, last observation carried forward; LS, least-squares; MADRS, Montgomery Åsberg Depression Rating Scale; MDD, major depressive disorder; MINI, Mini-International

Neuropsychiatric Interview; MOAA/S, Modified Observer's Assessment of Alertness/Sedation scale; SD, standard deviation; SE, standard error; TRD, treatment-resistant depression.

Acknowledgments

We acknowledge Sandra Norris, PharmD of the Norris Communications Group LLC for medical writing assistance and Ellen Baum, PhD (Janssen Global Services, LLC) for additional editorial support.

The abstract of this paper was presented at the European College of Neuropsychopharmacology (ECNP) Congress 2020 as a poster. The posters abstract was published in the Supplement 33rd ECNP Congress – Posters in European Neuropsychopharmacology (2020) 40, S420-421: <https://www.sciencedirect.com/science/article/pii/S0924977X20308191/pdf?md5=f447f43d1745ae592464b62756aa3fda&pid=1-s2.0-S0924977X20308191-main.pdf>.

It was also presented at the Psych Congress 2020: <https://www.psychiatryadvisor.com/home/conference-highlights/psych-congress-2020-coverage/effect-of-benzodiazepines-on-esketamine-nasal-spray-in-patients-with-major-depressive-disorder-and-suicidal-ideation/>) and at the German Association for Psychiatry, Psychotherapy and Psychosomatics Congress (DGPPN) Congress 2020, Berlin.

Author Contributions

Robert Murray conducted the statistical analyses. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. All authors meet ICMJE criteria and all those who fulfilled those criteria are listed as authors.

Funding

The ASPIRE I and ASPIRE II studies were funded by Janssen Research & Development, LLC, Titusville, NJ, USA. Employees of the Sponsor, as noted in Author Contributions, were involved in data analysis or interpretation and/or other aspects pertinent to the studies. Authors had full access to all of the data in the study, were involved

in writing and/or revising the manuscript, and had final responsibility for the decision to submit for publication.

Disclosure

Drs. Bettina Diekamp, Stephane Borentain, Dong-Jing Fu, Kristin Heerlein, Qiaoyi Zhang, Maju Mathews, and Mr. Robert Murray are employees of Janssen-Cilag GmbH or Janssen Research & Development, LLC and some hold company equity. Dr. med. Cornelius Schüle has served as a member of advisory boards for Janssen-Cilag GmbH and Janssen Pharmaceutica NV. The authors report no other conflicts of interest in this work.

References

- Vandeleur CL, Fassassi S, Castelao E, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. *Psychiatry Res*. 2017;250:50–58. doi:10.1016/j.psychres.2017.01.060
- Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. *JAMA Psychiatry*. 2018;75(4):336–346. doi:10.1001/jamapsychiatry.2017.4602
- Dong M, Zeng LN, Lu L, et al. Prevalence of suicide attempt in individuals with major depressive disorder: a meta-analysis of observational surveys. *Psychol Med*. 2019;49(10):1691–1704. doi:10.1017/S0033291718002301
- Sokero TP, Melartin TK, Rytsälä HJ, Leskelä US, Lestelä-Mielonen PS, Isometsä ET. Suicidal ideation and attempts among psychiatric patients with major depressive disorder. *J Clin Psychiatry*. 2003;64(9):1094–1100. doi:10.4088/JCP.v64n0916
- Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. *Am J Psychiatry*. 2007;164(7):1029–1034. doi:10.1176/ajp.2007.164.7.1029
- Wasserman D, Rihmer Z, Rujescu D, et al. European Psychiatric Association. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. *Eur Psychiatry*. 2012;27(2):129–141. doi:10.1016/j.eurpsy.2011.06.003
- van der Feltz-cornelis CM, Sarchiapone M, Postuvan V, et al. Best practice elements of multilevel suicide prevention strategies: a review of systematic reviews. *Crisis*. 2011;32(6):319–333. doi:10.1027/0227-5910/a000109
- Bushnell GA, Stürmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001–2014. *JAMA Psychiatry*. 2017;74(7):747–755. doi:10.1001/jamapsychiatry.2017.1273
- Winkler D, Kaltenboeck A, Frey R, Kasper S, Pjrek E. Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria. *Compr Psychiatry*. 2019;93:20–26. doi:10.1016/j.comppsy.2019.06.004
- Davidson JR. Major depressive disorder treatment guidelines in America and Europe. *Clin Psychiatry*. 2010;71(SupplE1):e04. doi:10.4088/JCP.9058se1c.04gry
- Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. *J Affect Disord*. 2001;65(2):173–177. doi:10.1016/S0165-0327(00)00254-8
- Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. *Eur Psychiatry*. 2013;28(1):7–20. doi:10.1016/j.eurpsy.2011.11.003
- Spravato™ (esketamine) nasal spray Prescribing Information. © Janssen Pharmaceutical Companies; 2020.
- Spravato (esketamine) Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf. Accessed March 29, 2021.
- Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). *J Clin Psychiatry*. 2020;81(3):19m13191. doi:10.4088/JCP.19m13191
- Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). *Int J Neuropsychopharmacol*. 2021;24(1):22–31. doi:10.1093/ijnp/pyaa068
- Ford N, Ludbrook G, Galletly C. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. *Aust N Z J Psychiatry*. 2015;49(12):1227. doi:10.1177/0004867415590631
- Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. *J Clin Psychopharmacol*. 2015;35(3):334–336. doi:10.1097/JCP.0000000000000316
- Albott CS, Shiroma PR, Cullen KR, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. *J Clin Psychiatry*. 2017;78(3):e308–e309. doi:10.4088/JCP.16l11277
- American Psychiatric Association: diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Arlington, TX: American Psychiatric Publishing; 2013.
- Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59(suppl 20):22–33, quiz 34–57.
- Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). *Br J Psychiatry*. 2008;192:52–58. doi:10.1192/bjp.bp.106.032532
- Melander H, Salmonson T, Abadie E, van Zwieten-boot B. A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. *Eur Neuropsychopharmacol*. 2008;18(9):623–627. doi:10.1016/j.euroneuro.2008.06.003
- Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? *Int Clin Psychopharmacol*. 2009;24(3):111–118. doi:10.1097/YIC.0b013e32832a8eb2
- Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). *J Trauma Stress*. 1988;1(1):125–136. doi:10.1023/A:1024465317902
- Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. *J Clin Psychopharmacol*. 1990;10(4):244–251.
- Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. *Am J Psychiatry*. 2008;165(3):342–351. doi:10.1176/appi.ajp.2007.06111868
- Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands study of depression and anxiety (NESDA). *J Clin Psych*. 2011;72(3):341–348. doi:10.4088/JCP.10m06176blu
- Andrashko V, Novak T, Brunovsky M, Klirova M, Sos P, Horacek J. The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. *Front Psychiatry*. 2020;11:844. doi:10.3389/fpsy.2020.00844

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and

is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>